Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Dec

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL